Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? George and Yanai Join Amneal’s Board

Major Changes Also Made At Latvia’s Olainfarm

Executive Summary

Two familiar industry figures have bolstered Amneal’s board, while Latvia’s Olanfarm has turned to a Sanofi executive for external expertise. Meanwhile, both Taro and Pfenex are recruiting CFOs.

You may also be interested in...



Patels Working To Build ‘Amneal 2.0’

Amneal reported a 20% drop in sales in the fourth quarter of 2019, primarily due to lower turnover from its generics business. The company’s co-CEOs are trying to revitalize the company and have launched 15 new products since returning midway through last year.

Who’s Hired? Teligent And Centrient Get New CEOs

Teligent CEO Jason Grenfell-Gardner has stepped down with immediate effect, while Centrient CEO Karl Rotthier is preparing to leave the role in March. Both firms have announced details of their replacements. Meanwhile, Stada has appointed a new chief financial officer.

Amneal Aims To Expand Internationally

Amneal has laid out ambitious plans for 2020 to deliver value and volume growth, including by expanding internationally, augmenting organic growth through M&A and capitalizing on its pipeline of ANDAs and development projects. The firm will seek to build on its launch of 38 products in 2019 as well as benefiting from recent key appointments to its board.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel